foxo4-dri senolytic human trial Molecular modelling of the FOXO4-TP53 interaction to design peptides for the elimination of senescent cancer cells FOXO4-DRI 10mg vial - Description

Etho BPC-157 with SNAC 1 0.5 mg BPC-157

It was originally derived from a protein fragment associated with gastric juice and studied for its protective effects on the gastrointestinal system. Since its development in the 1990s, research has expanded into musculoskeletal healing, where it has shown promising effects in animal models involving tendon, ligament, muscle, and bone injuries. One important caveat regarding BPC-157 is that it is not FDA-approved for human use, and most of what we know comes from preclinical research

A 120mg combination blend 100mg NAD+, 10mg MOTS-c, and 10mg 5-Amino-1MQ

This enhanced formulation combines Semaglutide , a powerful GLP-1 receptor agonist, with vitamin B12 to promote metabolic function, support energy levels, and reduce common side effects such as fatigue or nausea

National Institutes of Health Office of Dietary Supplements

ROS disrupts brain ECs tight junctions arrangement via RhoA/PI3K/PKB pathway (Schreibelt et al., 2007)